Core Insights - Veeva Systems announced that 13 of the top 20 biopharmaceutical companies have adopted Veeva Link Key People to enhance customer engagement and support AI initiatives globally [1] - The adoption of Link Key People has led to the addition of 38 new customers, with three of the top 20 biopharmas making it their global standard in the past year [1] Customer Engagement and AI Integration - Access to Veeva Link Key People strengthens data-driven decision-making, enhances targeting, and fosters engaging healthcare professional (HCP) interactions, ultimately benefiting patient healthcare [2] - The data from Link Key People has become integral to Bayer's data strategy, enriching AI-driven platforms and providing actionable business insights for long-term patient benefits [2] Value Delivery and Innovations - Link Key People provides valuable insights for medical and commercial teams, while analytics teams utilize Link data to enhance their AI models [3] - Recent innovations, including AI-powered summaries and personalized notifications, improve customer interactions and reveal new engagement opportunities [3] - The Link Direct Data API offers high-speed access to Veeva's data, further enhancing data accessibility for teams [3] Industry Impact and Strategic Relationships - The increasing use of Link Key People among top biopharmas and emerging biotechs is expected to advance engagement across the industry, leveraging deep Key Opinion Leader (KOL) data for strategic relationships [4] Veeva Data Cloud Integration - Link Key People is part of Veeva Data Cloud, which includes Veeva OpenData, Veeva HCP 360, and Veeva Compass, utilizing Veeva's Common Data Architecture to connect data and software [5] Company Overview - Veeva Systems provides industry cloud solutions for life sciences, serving over 1,500 customers, from large biopharmaceutical companies to emerging biotechs, with a commitment to innovation and customer success [6]

Frees sites from duplicate data entry and connects EHR and EDC for higher quality trial data, faster About Veeva Systems Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, inc ...

Veeva Systems (VEEV) ended the recent trading session at $225.28, demonstrating a +2.53% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.55% for the day. Elsewhere, the Dow gained 0.63%, while the tech-heavy Nasdaq added 0.91%. Prior to today's trading, shares of the provider of cloud-based software services for the life sciences industry had lost 1.53% lagged the Medical sector's gain of 0.19% and the S&P 500's gain of 0.71%.Analysts and investors ...

Market Overview - U.S. equity markets ended the fourth quarter positively, with the S&P 500 and Nasdaq 100 rising 2.4% and 2.6% respectively, while the Dow Jones Industrial Average led with a 3.6% return [2] - The Russell 1000 Growth Index lagged, increasing only 1.1% as investors shifted from high-growth technology stocks to more defensive sectors [2] - The quarter was marked by significant volatility, influenced by a 43-day government shutdown that affected market transparency and risk appetite [2] Economic and Monetary Policy - Approximately 83% of S&P 500 companies reported positive earnings surprises, indicating a broadening economic recovery beyond the "Magnificent Seven" [4] - The Federal Reserve implemented two 25-basis point cuts, bringing the federal funds rate to a range of 3.50% to 3.75% by year-end, and concluded its quantitative tightening program [4] - The Fed's balance sheet expanded by approximately $100 billion to $6.6 trillion, reflecting a shift from "abundant" to "ample" bank reserves [4] Sector Performance - Ithaka's portfolio underperformed the Russell 1000 Growth Index by 700 basis points, with stock selection detracting 740 basis points from relative performance [6] - Positive relative returns were generated in the Materials and Processing sector, while Technology and Consumer Discretionary sectors were significant sources of underperformance [7] - Weakness in Technology was attributed to fears of AI disintermediating software stocks, while Consumer Discretionary faced pressures from consumer spending concerns [7] Top Contributors and Detractors - Top contributors included Intuitive Surgical (26.6% return), Advanced Micro Devices (32.4%), and Alphabet (28.9%), driven by strong earnings and positive investor sentiment [9][10][12] - Major detractors were ServiceNow (-16.8%), Netflix (-21.8%), and Veeva Systems (-25.1%), with concerns over AI impacts and unexpected financial disclosures affecting stock performance [9][15][16] Investment Strategy and Outlook - Ithaka initiated three new positions and eliminated four during the quarter, with a trailing 12-month turnover of 22.1% [17] - The investment approach focuses on long-term wealth creation through concentrated positions in high-quality companies with strong management and favorable market conditions [4][19] - The narrative around AI is shifting towards tangible productivity gains, suggesting that the economic opportunities from AI will continue to expand [18]

Company Overview - Veeva aims to build the industry cloud for life sciences, integrating software, data, and consulting to enhance efficiency and effectiveness across R&D, manufacturing, and commercial sectors [3]. Leadership and Presentation - Brian Van Wagener, the CFO of Veeva, presented the company's vision and operational model, emphasizing the importance of clear communication regarding the company's direction and opportunities [2]. Key Metrics and Goals - The presentation included key metrics that illustrate Veeva's operational model and portfolio, aiming to provide a straightforward understanding of the company's position and future trajectory [2].

Veeva Systems FY Conference Summary Company Overview - **Company**: Veeva Systems (NYSE: VEEV) - **Industry**: Life Sciences Software and Consulting - **Market Opportunity**: Approximately $20 billion market with 16% penetration, indicating significant growth potential [6][7] Core Business Model and Vision - **Vision**: To build the industry cloud for life sciences, integrating software, data, and consulting to enhance efficiency across R&D, manufacturing, and commercial sectors [3][6] - **Values**: Emphasis on integrity, customer success, employee success, and speed [4][5] - **Public Benefit Corporation**: Veeva is the first public company to convert to a Public Benefit Corporation, balancing the interests of shareholders, customers, employees, and society [6] Product Portfolio - **Product Suites**: Veeva offers over 10 product suites and more than 50 products, categorized into: - Development Cloud: Clinical, regulatory, and safety management - Quality Cloud: Manufacturing quality assurance - Commercial Cloud: Sales, medical, and marketing solutions - Data Cloud: Data management and analytics [7][9] - **Unique Selling Proposition**: The "suite effect" allows customers to benefit from interconnected products, reducing integration complexities [10][11] Market Dynamics and Trends - **AI Integration**: AI is becoming integral in life sciences, enhancing productivity in drug discovery and clinical trials [17][18] - **Industry Connectivity**: Increased collaboration among stakeholders, leading to faster and more inclusive clinical trials [18] - **Changing Commercial Models**: Shift towards ongoing care and precision medicine as standard practice [18] Financial Performance and Growth Strategy - **Revenue Growth**: Expected revenue of $3.17 billion for the current fiscal year, representing a 15% growth rate [30] - **Long-term Goals**: Targeting $6 billion in revenue by 2030, implying a 13% annual growth rate [27] - **Investment Focus**: Significant investment in product development, with a commitment to maintaining high operating margins (expected 45% non-GAAP) [30][31] Competitive Landscape - **Main Competitors**: Salesforce in CRM and Medidata in clinical areas, with many competitors being niche providers [36][37] - **Market Share**: Veeva holds over 80% market share in biopharma CRM, expecting to maintain over 70% post-migration to Vault CRM [23][24] Capital Allocation and M&A Strategy - **Cash Position**: Over $6.5 billion in cash with no debt, allowing for both M&A and shareholder returns [32][33] - **Share Repurchase Program**: Announced a $2 billion share repurchase over two years to return value to shareholders [33] - **M&A Focus**: Targeting strategic acquisitions to enhance product excellence and expand into cross-industry software [39][40] Customer Engagement and Consulting - **Customer Success**: Veeva's products are designed to be mission-critical, leading to high customer retention and advocacy [14][45] - **Business Consulting**: Growing segment focused on helping customers optimize business processes and implement technology effectively [50][51] Crossix Business Insights - **Digital Marketing Growth**: Crossix continues to show strong growth in digital marketing and measurement, with potential to match CRM size in the future [52][54] - **Market Leadership Potential**: Positioned to gain further market share in a growing digital marketing landscape [53][54] Profitability and Margin Management - **Profitability Strategy**: Focus on sustainable growth without artificial margin targets, allowing for necessary investments in innovation [55][56] - **Operating Leverage**: Anticipated improvements in margins as Salesforce royalties decline and investments in AI and data products yield returns [56] This summary encapsulates the key points from the Veeva Systems FY Conference, highlighting the company's strategic vision, product offerings, market dynamics, financial performance, and future growth opportunities.

J.P. Morgan Healthcare Conference January 13, 2026 Brian Van Wagener Chief Financial Officer Safe Harbor and Other Information This presentation and associated commentary contain forward-looking statements regarding Veeva's future plans and expected performance, market size and opportunity, and financial outlook, including guidance provided as of November 20, 2025, about Veeva's expected future financial results and long-term financial goals for 2030. These statements are based on our current expectation an ...

Imaginative depiction of Okta office lobby with illuminated Okta logo and tablet showing secure identity software, reflecting cybersecurity business confidence. Key Points With shares depressed from highs, three software stocks just announced significant buyback programs. These companies, both explicitly and implicitly, are expressing their views that investors undervalue their shares. After falling nearly 30%, analysts see +40% upside in Guidewire. Interested in Okta, Inc.? Here are five stocks we li ...

Core Viewpoint - Veeva Systems will participate in the J.P. Morgan 2026 Healthcare Conference, with CFO Brian Van Wagener presenting on January 13, 2026 [1] Company Overview - Veeva is the global leader in cloud software for the life sciences industry, serving over 1,500 customers, including major pharmaceutical companies and emerging biotechs [2] - As a Public Benefit Corporation, Veeva aims to balance the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves [2] Disclosure Practices - Veeva utilizes its investor relations website to disclose material non-public information and announce upcoming investor conferences, complying with Regulation FD [3]

Core Viewpoint - Veeva Systems has been upgraded to Buy from Hold by Truist Securities, with a price target set at $275.00, indicating an attractive entry point for investors [1] Group 1: Revenue and Market Position - CRM now constitutes a smaller portion of Veeva's overall revenue, with any revenue headwinds from customer migrations expected to be deferred beyond fiscal 2027 and spread over multiple years [2] - Despite increased competition in the pharma CRM sector, Veeva maintains a dominant market position [2] Group 2: Growth and Risk Profile - With CRM-related risks largely mitigated, Veeva is experiencing strong execution in growth areas such as Crossix and early momentum in artificial intelligence initiatives [3] - These factors contribute to durable growth and margin stability, making the current risk-reward profile attractive [3]